1. Scrip
  2. >>R&D

Sirnaomics Bets On RNAi In China With First IND Approval

 
• By Brian Yang

Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.

Alan Lu
Alan Lu, EVP, Sirnaomics

Small interfering RNA (siRNA) is a relatively new concept in China, where most innovative companies are betting on either small molecule or monoclonal antibodies for cancer treatment.

Headquartered in Gaithersburg, MD with subsidiaries in Suzhou and Guangzhou, China, Sirnaomics Inc. has filed an investigative new drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.